Cipla

# Pregnancy-Specific Patient Reminder Card

## Before starting Fingolis (fingolimod) treatment

**Fingolis (fingolimod) is contraindicated in pregnant women and women of child-bearing potential (including adolescents) not using effective contraception.**

At treatment start and then regularly, your doctor will inform you about the teratogenic risk (causes defects to unborn babies) and required actions to minimise this risk.

A pregnancy test must be conducted and the negative result verified by a doctor before starting treatment.

Your doctor will inform you about the need for effective contraception while on treatment and for 2 months after discontinuation. Talk to your doctor about the most effective contraception options available to you.

Please read the Fingolis Patient Guide Leaflet provided by your doctor.

## While you are taking Fingolis (Fingolimod)

While on treatment women must not become pregnant.

Patients must use effective contraception while taking Fingolis.

Women must not become pregnant during treatment and for 2 months after discontinuing treatment.

Pregnancy tests must be repeated at suitable intervals.

Your doctor will provide regular counselling about Fingolis serious risks to the foetus.

If you become pregnant or if you want to become pregnant please discuss this with your doctor because Fingolis treatment must be discontinued.

In the event of a pregnancy your doctor will provide counselling.

Your doctor will give you medical advice regarding the harmful effects of Fingolis to the foetus and will provide an evaluation of the potential outcome.

## After stopping Fingolis (fingolimod) treatment

Inform your doctor immediately if you believe your MS is getting worse (e.g. weakness or visual changes) or ifyou notice any new symptoms after stopping treatment with Fingolis due to pregnancy.

Effective contraception is needed for 2 months after stopping Fingolis treatment because of the length of time it takes for Fingolis to leave the body.

## Reporting of side effects

If you get side effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the information leaflet that comes in the pack.

Please report suspected adverse drug reactions (ADRs) to the Therapeutic Goods Administration (TGA) via website: www.tga.gov.au/reporting-problems

By reporting side effects, you can help provide more information on the safety of this medicine

All pregnancies should be reported to Cipla on 1800-569-074 and via email to drugsafety@cipla.com